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Melanoma cell adhesion molecule (MCAM) is a cell-surface adhesion molecule expressed on over 70% of metastatic
melanoma cells but not expressed in normal melanocytes in vivo. Protein levels of MCAM correlate with aggressive
invasive behavior of melanoma cells in vitro and in vivo. Here we demonstrate that endothelin-1 (ET-1) upregulates
MCAM protein in primary human melanocytes. MCAM upregulation by ET-1 occurs irrespective of degree of me-
lanocyte pigmentation and is dose-responsive. The drug BQ788 is an endothelin-B (ETB) receptor antagonist and
inhibits upregulation of MCAM by ET-1. In addition, endothelin-3 (ET-3) and N-succinyl-[Glu9, Ala11, 15]-ET-1-1620,
both selective ETB agonists, are potent upregulators of MCAM. These demonstrate a critical role for the ETB
receptor in the upregulation of MCAM by ET-1 and related isoforms. MCAM mRNA abundance is also increased by
ET-1 stimulation, thus the mechanism of MCAM protein upregulation may occur at the level of transcription. Our
previous studies have demonstrated that ET-1 downregulates E-cadherin in melanocytes and melanoma cells.
Since E-cadherin is a melanoma invasion suppressor, and MCAM is a melanoma invasion promoter, ET-1 may
promote melanoma invasion and metastasis through the regulation of adhesion molecule expression.
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Melanoma cell adhesion molecule (MCAM) is a 113 kDa
cell-surface adhesion molecule expressed by smooth mus-
cle cells and vascular endothelium in normal adult tissues
but is rarely expressed in carcinoma cells (Mintz-Weber and
Johnson, 2000). MCAM, however, is expressed in over 70%
of metastatic melanomas and levels of expression increase
with increasing vertical thickness of tumors and aggressive
invasive behavior (Bar-Eli, 1999). Nevus cells (cells from skin
‘‘moles’’ demonstrating cytologic atypia) express low levels
of MCAM (Bar-Eli, 1999), whereas normal melanocytes
rarely express MCAM in vivo (Bar-Eli, 1999). Enforced ex-
pression of MCAM in MCAM-negative melanoma cells con-
fers invasiveness and metastatic potential in vivo and
in vitro (Bar-Eli, 1999; Mintz-Weber and Johnson, 2000).
MCAM also confers an increase in adhesion to human end-
othelial cells, laminin as well as homotypic cell: cell adhe-
sion (Bar-Eli, 1999).
The mechanism for MCAM upregulation during me-
lanoma progression is unknown (Karlen and Braathen,
1999). There is no evidence that MCAM undergoes chro-
mosomal translocation, mutation or amplification thus, it
has been postulated that MCAM upregulation occurs sec-
ondary to an aberrant cytokine network present in the
epidermal microenvironment (Karlen and Braathen, 1999).
Endothelin-1 (ET-1) is a 21-amino acid peptide secreted by
epidermal keratinocytes that may participate in such a net-
work modulating MCAM expression in vivo.
ET-1 secretion by epidermal keratinocytes is induced by
ultraviolet (UV) irradiation (Imokawa et al, 1997). Once se-
creted, ET-1 can then bind to high-affinity cell-surface ET
receptors present on melanocytes and melanoma cells
present in the epidermis of the skin (Hara et al, 1995;
Imokawa et al, 1996, 1997). ET-1 stimulates a variety of
physiologic responses in melanocytes and melanoma cells
including an increase in dendricity, mitogenesis, chemotaxis,
and pigment production (Yohn et al, 1994; Hara et al, 1995;
Imokawa et al, 1996; Imokawa et al, 1997). The endothelin-
B (ETB) receptor is a melanoma tumor progression marker
and ETB blockade induces melanoma cell death and growth
arrest in vivo and in vitro (Lahav et al, 1999; Demunter et al,
2001). Thus, the endothelin pathway plays an important role
in melanoma development and progression. The exact na-
ture of this role has yet to be elucidated, however.
An alteration in adhesive properties is commonly seen
during tumor progression and is critical to the development
of aggressive metastatic behavior of cancer cells. It is
therefore important to identify those factors promoting
changes in adhesion during the early transformation of nor-
mal cells to cancer cells. E-cadherin expression is important
for maintenance of the normal melanocyte phenotype and is
commonly downregulated during melanoma development
(Hsu et al, 1996, 2000). E-cadherin suppresses melanoma
invasion in vivo and in vitro (Hsu et al, 1996, 2000). We have
previously demonstrated that ET-1 is a potent downregula-
tor of E-cadherin in melanocytes and melanoma cells (Jam-
al, 2000; Jamal and Schneider, 2002). Here, we demon-
strate that ET-1 is also a potent upregulator of MCAM, a
known promoter of melanoma invasion. This provides fur-
ther evidence that ET-1 plays a critical role in altering the1Co-first authors.
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adhesive properties of melanocytes during tumor progres-
sion to promote metastasis and invasion.
Results
ET-1 upregulates MCAM protein in primary human me-
lanocytes To determine whether ET-1 altered protein levels
of MCAM, four different primary human melanocyte cultures
were stimulated with 10 nM ET-1 over a 7-d time course. We
selected two cultures derived from lightly pigmented indi-
viduals and two from darkly pigmented individuals, in case
degree of pigmentation had an impact on the observed re-
sponse. The prolonged time course was chosen since ET-1
is known to elicit delayed responses in melanocytes (Hara
et al, 1995; Jamal and Schneider, 2002). As shown in Fig 1,
ET-1 induced a dramatic increase in protein levels of MCAM
in all four cell cultures. There was no apparent difference in
the response of lightly pigmented versus darkly pigmented
melanocytes. As expected, the kinetics for this response
were delayed, with MCAM upregulation being evident by
the 4-d time point in three of four cultures (upregulation
occurred by day 5 in the remaining culture).
Next, the concentration of ET-1 used to stimulate cells
was titrated in order to determine whether upregulation of
MCAM by ET-1 was dose-responsive. As shown in Fig 2,
protein levels of MCAM increased with increasing ET-1
concentrations. This suggests that the response is occur-
ring secondary to ET-1 addition. Although it is possible that
other factors in the culture medium contribute to this re-
sponse, overall these data suggest that ET-1 is a potent
upregulator of MCAM.
ETB receptor antagonist BQ788 blocks MCAM upregu-
lation by ET-1 Melanocytes express two high-affinity ET-1
receptors, the endothelin-A (ETA) and the ETB subtype
(Baynash et al, 1994). In order to determine which receptor
subtype mediates upregulation of MCAM by ET-1, we pre-
treated melanocytes with a selective ETA receptor antago-
nist (BQ610) or a selective ETB receptor antagonist (BQ788)
prior to ET-1 addition. Cells were harvested at the 5-d time
point and MCAM western blot analysis performed. As
shown in Fig 3, ET-1 alone, once again, was a potent up-
regulator of MCAM. Pre-treatment of cells with ETA receptor
antagonist BQ610 failed to block this upregulation. In sharp
contrast, pre-treatment of cells with ETB receptor antago-
nist BQ788 significantly reduced MCAM upregulation by ET-
1. These results suggest that activation of the ETB receptor
plays a critical role in the upregulation of MCAM by ET-1. In
addition, the ability of BQ788 to block this response indi-
cates that MCAM upregulation occurs as a direct or indirect
effect of ET stimulation of the ETB receptor and is not an
in vitro artifact.
Selective ETB receptor agonists upregulate MCAM with
faster kinetics than ET-1 Although ET-1 binds with equal
affinity to both the ETA and ETB receptor subtypes, the
endothelin isoform endothelin-3 (ET-3) demonstrates a
much greater affinity for ETB than ETA and is a potent ETB
Figure 1
Endothelin-1 (ET-1) upregulates melanoma cell adhesion molecule
(MCAM) in human primary melanocytes. Four different human me-
lanocyte primary cell cultures were stimulated with 10 nM ET-1 over a
7-d time course. Cells were harvested at the indicated time points and
lysates were normalized for protein content. Samples were analyzed by
western blot using anti-MCAM antibodies. Actin was used as an in-
ternal control. Unstimulated control samples are in lanes labeled ‘‘UN’’
and 12-O-tetradecanoyl phorbol-13-acetate (TPA) depletion did not in-
duce MCAM in these samples. Cultures D90 and D110 were derived
from darkly pigmented individuals. Cultures L110 and L80 were derived
from lightly pigmented individuals. Cell passage numbers are indicated
and range from eighth to 13th passage in this figure. Figures are rep-
resentative of three independent trials.
Figure2
Upregulation of melanoma cell adhesion molecule (MCAM) by
endothelin-1 (ET-1) is dose-responsive. Melanocytes were stimulat-
ed for 5 d with ET-1 at concentrations ranging from 0.25 to 10 nM.
Samples were harvested and MCAM western blot analysis was per-
formed as described above. All four cultures tested demonstrated dose
responsiveness of MCAM upregulation by ET-1 (results shown for two
cultures only). Figures are representative of three independent trials.
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agonist (Huggins and Pelton, 1997). Furthermore, the syn-
thetic peptide IRL-1620, in addition to its being a potent ETB
agonist, binds exclusively to ETB and is therefore a useful
tool in dissecting ETB-specific signaling pathways (Huggins
and Pelton, 1997). In the upper panels of Fig 4, cells were
stimulated with 10 nM ET-3 or IRL-1620 over a 6-d time
course. As shown, both ETB selective agonists induced a
dramatic increase in MCAM protein levels. In the lower
panels, melanocytes were stimulated for 2 d with ET-3 or
IRL-1620 and a dramatic increase in MCAM protein levels
was also observed. As shown, MCAM upregulation by ET-3
and IRL-1620 occurred with faster kinetics than those ob-
served using ET-1. This upregulation was strongly evident
by the 2-d time point (no upregulation of MCAM was ob-
served prior to this time point, data not shown). These re-
sults reinforce our earlier data indicating that the ETB
signaling pathway mediates MCAM upregulation by ET-1.
ET-1 does not upregulate MCAM in melanoma cells We
next tested five human melanoma cell lines to determine
whether ET-1 induced MCAM expression in a manner sim-
ilar to that observed in melanocytes. SKMEL28, M20,
WM2664, WM1232, and SB2 cells were stimulated with
ET-1, ET-3, and IRL-1620 as described previously. We were
unable to detect upregulation of MCAM in these melanoma
cells lines using these agents. As shown in Fig 5, ET-3 did
not upregulate MCAM in either SKMEL28 or SB2 cells. It is
apparent, however, that SKMEL28 cells express constitutive
levels of MCAM that are significantly higher than those ex-
pressed by D15’ human melanocytes whether at baseline or
when induced by ET-3. In addition it is also clear in Fig 5 that
SB2 human melanoma cells express far lower levels of
MCAM than either SKMEL28 cells or human melanocytes.
We were unable to detect any significant MCAM protein in
these cells even when the total amount of protein was tit-
rated to a 30-fold excess of that used in this figure. All other
melanoma cell lines expressed MCAM constitutively at lev-
els similar to those observed in SKMEL28 cells (data not
shown). This data suggests that ET-1 is unable to induce
MCAM in melanoma cells expressing high constitutive lev-
els of MCAM.
ET-1 stimulation increases MCAM mRNA abundance in
melanocytes In order to investigate the mechanism of
MCAM upregulation by ET-1, we performed northern blot
analysis. Cells were stimulated over a 7-d time course with
10 nM ET-1 and then harvested for RNA at different time
Figure 3
BQ788 blocks melanoma cell adhesion molecule (MCAM) upreg-
ulation by endothelin-1 (ET-1). Melanocyte cultures were stimulated
with 10 nM ET-1 for 5 d. Where indicated, cells were additionally treated
with either endothelin-A (ETA) antagonist BQ610 or endothelin-B (ETB)
antagonist BQ788 at a 10-fold molar excess. Samples were harvested
and MCAM western blot analysis was performed as described above.
All four cultures tested demonstrated BQ788-mediated inhibition
of MCAM upregulation by ET-1 (results are shown for three cultures).
Figures are representative of three independent trials.
Figure4
Selective endothelin-B (ETB) agonists upregulate melanoma cell
adhesion molecule (MCAM). In the upper panels, L150 cells were
stimulated over a 6-d time course with either 10 nM endothelin-3 (ET-3)
or 10 nM IRL-1620. In the other panels, cells were stimulated for 2 d
with either 10 nM ET-3 or 10 nM IRL-1620. Samples were harvested
and MCAM western blot analysis was performed as described above.
Figures are representative of three independent trials.
Figure5
Endothelin-1 (ET-1) does not upregulate melanoma cell adhesion
molecule (MCAM) in melanoma cells. Extracts from D150 human
melanocytes, SKMEL28 (SK) melanoma cells and SB2 melanoma cells
were stimulated with endothelin-3 (ET-3) for 2 d. Lysates normalized for
protein content were analyzed by MCAM western blot as described
previously.
ENDOTHELIN UPREGULATES MCAM IN MELANOCYTES 1137123 : 6 DECEMBER 2004
points. As shown in Fig 6, MCAM mRNA abundance grad-
ually increased over the duration of the assay and peaked at
the 7-d time point. This gradual increase in mRNA abun-
dance is consistent with the gradual increase in MCAM
protein levels observed in response to ET-1 stimulation.
These data suggest that the mechanism of MCAM upreg-
ulation by ET-1 is either transcriptional or affects MCAM
mRNA stability.
Discussion
We have clearly demonstrated that ET-1 is a potent upreg-
ulator of MCAM in normal human melanocytes and that the
ETB receptor, which is a melanoma tumor progression mark-
er (Demunter et al, 2001), is critical for this response. The ETB
receptor antagonist BQ788 substantially reduced the ability
of ET-1 to upregulate MCAM. The failure of BQ788 to com-
pletely block this response may reflect the fact that although
BQ788 receptor binding is competitive and reversible, ET-1
binding is irreversible (Huggins and Pelton, 1997). Thus, there
may have been a small amount of ET-1 signaling occurring
even in the presence of the antagonist.
ET-1 activates both the ETA and ETB receptors whereas
ET-3 and IRL-1620 are selective ETB agonists (Huggins
and Pelton, 1997). Since upregulation of MCAM by ET-3 and
IRL-1620 occurs with faster kinetics than those observed
with ET-1, it is possible that co-activation of the ETA and ETB
receptors by ET-1 results in cross-talk between the two
pathways that antagonizes ETB-dependent signaling. Pro-
longed ET-1 stimulation of cells may cause a selective de-
sensitization of the ETA pathway, after which time, ETB
signaling would predominate and result in a delayed up-
regulation of MCAM. Given our results, it is likely that in
order for MCAM to be upregulated in melanocytes by ET-1
in vivo, a prolonged exposure to ET-1 would be required.
Since ET-1 is normally secreted by the skin in response to
UV irradiation (Imokawa et al, 1992; Ahn et al, 1998), there
must exist a mechanism to prevent the upregulation of
MCAM by ET-1 secreted in response to physiologic doses
of sunlight. After UV-irradiation, ET-1 levels peak at 2 d,
gradually falling back to baseline several days later (Ahn
et al, 1998). It is therefore reasonable to expect that me-
lanocytes would be resistant to MCAM upregulation by ET-1
for a period of several days and this is what our data dem-
onstrate. An aberrant or constitutive exposure to ET-1,
however, may eventually lead to MCAM upregulation in
these cells. Early in melanoma progression, atypical me-
lanocytes secrete factors such as interleukin-1-a, and tumor
necrosis factor-a (Moretti et al, 1999), which are known to
stimulate ET-1 secretion by keratinocytes. Keratinocyte-
derived ET-1, would upregulate MCAM in the atypical
melanocyte and promote invasive behavior. Thus it can be
seen that signals from the atypical melanocyte may trigger
an aberrant signaling loop involving adjacent keratinocytes
with potentially disastrous effects within the epidermal mi-
croenvironment. Interestingly, constitutive ET-1 secretion is
seen in the epidermis of skin samples obtained from lent-
iginous proliferations of melanocytes (Kadono et al, 2001)
and 70% of melanomas arise in association with such pro-
liferations (Kadono et al, 2001).
ET-1 did not upregulate MCAM in any of the five me-
lanoma cell lines tested. It is likely that ET-1 cannot upreg-
ulate MCAM when it is being expressed maximally. Previous
studies have shown that MCAM is uninducible when ex-
pressed at constitutively high levels in melanoma cells
(Karlen and Braathen, 1999). Since SB2 melanoma cells
express less MCAM than unstimulated melanocytes, it is
likely that endogenous MCAM is not expressed to any ap-
preciable degree in these cells and is not readily inducible.
MCAM mRNA abundance as determined by northern blot,
increases gradually in response to ET stimulation, and this
may be due to an ET-dependent increase in transcription.
The MCAM promoter contains a Ca2þ /cAMP responsive
element binding protein (CREB) binding motif and factors
such as forskolin, that increase intracellular cyclic adeno-
sine monophosphate (cAMP) concentrations in cells, have
been shown to upregulate MCAM (Rummel et al, 1996;
Karlen and Braathen, 1999). Interestingly, ET-1 is a known
activator of CREB and induces an ET-1-dependent phos-
phorylation of this important transcription factor (Tada et al,
2002; Harrison et al, 2004). MCAM upregulation by forskolin
stimulation of cells results in maximal upregulation of
MCAM protein levels at 48 h (Rummel et al, 1996), and
thus the kinetics of this response are identical to those ob-
served for MCAM upregulation in melanocytes in response
to ET-3 or IRL-1620. Our future studies will investigate the
role of CREB in MCAM upregulation by ET-1.
The endothelins play an important role in tumor progres-
sion in many different types of carcinomas and blockade of
the endothelin signaling cascades using ET receptor antag-
onists is showing promise in the treatment of advanced
prostate cancer (Carducci et al, 2002, 2003). It is now clear
from numerous studies that the ET-1/ETB pathway also plays
a vital role in melanoma progression and viability (Lahav
et al, 1999; Demunter et al, 2001). Our studies provide further
clues as to the role of this pathway in altering the adhesive
properties of melanocytes and melanoma cells such that
invasion and metastasis are favored. Overall the ET-1/ETB
pathway represents an excellent target for future therapeu-
tic intervention in the treatment of melanoma.
Figure 6
Endothelin-1 (ET-1) increases the abundance of melanoma cell
adhesion molecule (MCAM) mRNA. Cells were stimulated with 10 nM
ET-1 over a 7-day time course and total RNA harvested. Northern blot
analysis using an MCAM-specific radiolabeled cDNA probe was per-
formed. GAPDH was used as an internal control. Identical results were
obtained using all four cultures tested. Results shown are from two
cultures and are representative of three independent trials.
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Materials and Methods
Cells and cell culture Human melanoma cells were cultured as
described previously (Jamal and Schneider, 2002). Human neona-
tal melanocytes were isolated from foreskin and culture conditions
as described previously (Tada et al, 1998) (Jamal and Schneider,
2002). Briefly, melanocyte growth medium consisted of MCDB153,
4% heat-inactivated fetal bovine serum (Cellgro, Mediatech, Ha-
rndon, Virginia), 5 mg per mL insulin, 13 mg per mL bovine pituitary
extract, 0.6 ng per mL basic fibroblast growth factor, 108 M 12-O-
tetradecanoyl phorbol-13-acetate (TPA), and 1 mg per mL a-to-
copherol (Invitrogen, Carlsbad, California). Two days prior to stim-
ulation with ET-1, ET-3, or IRL-1620 (Bachem, King of Prussia,
Pennsylvania), TPA was removed from the medium. During ET
stimulations, TPA-free culture medium was changed every other
day with fresh ET added. BQ610 and BQ788 (Bachem) at a final
concentration of 1 mM were added to cells 1 hour prior to ET ad-
dition. All culture reagents were purchased from Sigma (St Louis,
Missouri) unless otherwise indicated. All experimental protocols
were approved by our institutional review board.
Western blot analysis Cells were lysed in RIPA buffer (1% NP40,
0.5% deoxycholic acid, 10 mM Tris pH 8.0, 150 mM NaCl, 50 mM
NaF, 0.2 mM sodium vanadate, 1 mM dithiothreitol, 1  protease
inhibitors—Complete-mini (Boehringer-Ingelheim, Ridgefield, Con-
necticut)). Lysates were quantitated using protein assay reagent
(Biorad, Hercules, California) and 10 mg of protein per sample was
used for 8% SDS-PAGE (sodium dodecyl sulfate polyacrylamide
gel electrophoresis). Proteins were electrophoretically transferred
and immobilized on nitrocellulose membranes (Schleicher and
Schuell, Keene, New Hampshire). The antibodies used were as fol-
lows: anti-MCAM (BD-Biosciences Pharmingen, San Diego, Cali-
fornia), anti-Actin (Santa Cruz Biotechnologies SC-8432, Santa Cruz,
California), and anti-mouse IgG-horseradish peroxidase (Santa Cruz
Biotechnologies, SC-2005). The ECL chemiluminescent system
(Amersham, Piscataway, New Jersey) was used for signal detection.
Northern blot analysis Total RNA was isolated from cells using
Trizol reagent (Invitrogen) and Rneasy columns (Qiagen, Valencia,
California). RNA at 10 mg per sample were separated by agarose
gel electrophoresis and transferred by capillary action and immo-
bilized onto nylon membranes (Genescreen, Perkin-Elmer Life &
Analytical Sciences, Boston, Massachusetts). An MCAM-specific
cDNA probe was generated by reverse transcriptase polymerase
chain reaction (RT-PCR) using the Access RT-PCR system (Prome-
ga, Madison, Wisconsin). The primer sequences were as follows:
sense (nt 185–206) 50-CCA AGG CAA CCT CAG CCA TGT C-30, an-
tisense (nt 598–622) 50-CTC GAC TCC ACA GTC TGG GAC GAC T-
30. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) probes
were similarly generated using the following primers: sense (nt 85–
106) 50-AAC GGA TTT GGT CGT ATT GGG C-30, antisense (nt 663–
684) 50-AGG GAT GAT GTT CTG GAG AGC C-30. The sizes of the
amplification products were verified by low molecular weight ag-
arose gel electrophoresis. The probes were radiolabeled using the
Rediprime random hexamer system (Amersham) and were hybrid-
ized to membranes using Perfect-Hyb solution (Sigma).
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